Live
Hindustan Unilever Ltd (HUL) is funding a research project to understand the immune response to SARS-CoV-2 among vaccinated people and vaccine efficacy among Indians.
The national-level research is being enabled by the office of the principal scientific adviser to the government of India’s programme that will work on collaborations between industry and academia.
HUL will also support additional analytical and data analyses through its R&D scientists to the consortium partners, it said.
- Orient Cables Eyes Rs 3,500 Crore Revenue By FY30
- Bangladesh Resumes Indian Wheat Purchases as Black Sea Disruptions Lift Prices
- Central Railway Recovers Rs 140 Crore In Ticket Fines
- Cosmic CRF Unit Bags Rs 25.94 Crore Combined Orders
- Arivihan in Talks to Raise Rs 96 Crore at Rs 570 Crore Valuation
“This is a first-of-its-kind national-level multi-centre study on long-term protection and immunogenicity of vaccines, in combination with an understanding of nutritional and ‘skin immunity’ status in the Indian population,” the company said in a statement on Tuesday.
Stock Covered in the news
